Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04953234
Other study ID # EF-37
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 23, 2021
Est. completion date April 26, 2021

Study information

Verified date July 2021
Source NovoCure Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is a prospective, pilot study aimed to test the safety of Tumor Treating Fields (TTFields) concomitant with best standard of care, for the treatment of hospitalized COVID-19 patients and continued treatment after hospitalization. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields) to the region of the organ to be treated, by means of surface, insulated electrode arrays.


Description:

PAST PRE-CLINICAL AND CLINICAL EXPERIENCE: Tumor Treating Fields (TTFields) are a non-invasive, regional antimitotic treatment modality with minimal toxicity which have been approved for the treatment of recurrent and newly diagnosed glioblastoma (GBM) by the Food and Drug Administration (FDA) in the United States and have obtained a CE mark in Europe for the same indications. TTFields concomitant with chemotherapy were also approved for malignant pleural mesothelioma under FDA's humanitarian device exemption. Cell culture study demonstrated that TTFields can significantly reduce corona virus infection and replication in human lung cells. DESCRIPTION OF THE STUDY: All patients included in this study are patients who are hospitalized due to COVID-19 disease. In addition, all patients must meet all eligibility criteria. Eligible patients will be enrolled to the study and will receive COVID-19 best standard of care treatment concomitant with TTFields using the NovoTTF-100L System. The patients will be treated continuously with the device until discharge from the hospital and until there are no limitations on activities. SCIENTIFIC BACKGROUND: Electric fields exert forces on electric charges similar to the way a magnet exerts forces on metallic particles within a magnetic field. These forces cause movement and rotation of electrically charged biological building blocks, much like the alignment of metallic particles seen along the lines of force radiating outwards from a magnet. Electric fields can also cause muscles to twitch and if strong enough may heat tissues. TTFields are alternating electric fields of low intensity. This means that they change their direction repetitively many times a second. Since they change direction very rapidly (150 thousand times a second), they do not cause muscles to twitch, nor do they have any effects on other electrically activated tissues in the body (brain, nerves and heart). Since the intensities of TTFields in the body are very low, they do not cause heating. The breakthrough finding made by Novocure was that alternating fields of very low intensity, now termed TTFields (Tumor Treating Fields), attenuate SARS-CoV-2 virus infection and replication. TTFields can be directed to a certain part of the body, leaving sensitive areas out of their reach. In conclusion, TTFields hold the promise of serving as a brand new treatment for COVID-19 disease with very few side effects.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date April 26, 2021
Est. primary completion date April 26, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age = 18 years. 2. Hospitalized with diagnosis of COVID-19 infection per reverse transcription polymerase chain reaction (RT-PCR) within 72 hours prior to treatment start. 3. SpO2 = 93% at sea level. 4. Lung involvement confirmed with chest imaging. 5. Able and willing to comply with all study procedures. 6. Female participants of childbearing age must use highly effective contraception. 7. All patients must understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted. Exclusion Criteria: 1. Receipt of any experimental treatment for COVID-19 prior to or during the study. 2. Assisted ventilation. 3. Critical illness: respiratory failure defined as oxygen saturation by pulse oximetry/inspired oxygen fraction (SpO2/FiO2) ratio < 150, septic shock, and/or multiple organ dysfunction. 4. Significant co-morbidities at baseline as determined by the investigator: 1. Clinically significant hematological, hepatic and renal dysfunction, defined as: Neutrophil count < 1.5 x 10^9/L and platelet count < 100 x 10^9/L; bilirubin > 1.5 x upper limit of normal (ULN); aspartate aminotransferase (AST) and/or alanine transaminase (ALT) > 2.5 x ULN; and serum creatinine > 2.5 mg/dL. 2. History of significant cardiovascular disease unless the disease is well controlled. Significant cardiac disease includes second/third degree heart block; significant ischemic heart disease; poorly controlled hypertension; congestive heart failure of the New York Heart Association (NYHA) Class IV (unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases). 3. History of arrhythmia that is symptomatic or requires treatment. Patients with atrial fibrillation or flutter controlled by medication are not excluded from participation in the study. 4. History of any psychiatric condition that might impair patient's ability to understand or comply with the requirements of the study or to provide consent. 5. Implantable electronic medical devices (e.g. pacemaker, defibrillator) in the upper torso. 6. Pregnancy or breast-feeding. 7. Known allergies to medical adhesives or hydrogel. 8. Unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's cooperation or other unspecified reasons that, in the opinion of the Investigator or sponsor, make the subject's enrollment incompatible with study objectives.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
NovoTTF-100L
Patients receive continuous TTFields treatment using the NovoTTF-100L device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the thorax. The treatment enables the patient to maintain regular daily routine.

Locations

Country Name City State
Israel Hadassah Medical Center Jerusalem

Sponsors (1)

Lead Sponsor Collaborator
NovoCure GmbH

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Frequency and severity of adverse events 2 months
Secondary All-cause mortality The proportion of participants who died by study Day 29. Day 1 through Day 29
Secondary Incidence of intensive care unit admission Day 1 through Day 29
Secondary Incidence of non-invasive ventilation or high-flow oxygen use Day 1 through Day 29
Secondary Incidence of invasive ventilation Day 1 through Day 29
Secondary Incidence of extracorporeal membrane oxygenation Day 1 through Day 29
Secondary Patient inflammatory status Inflammatory status measured as the difference in C reactive protein (CRP), D-dimer and ferritin blood levels from baseline on days 3, 8 and 11 until discharge. Day 3, 8, and 11
Secondary Duration of hospitalization Day 1 through Day 29
Secondary Time to recovery Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale: 1) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Not hospitalized, no limitations on activities. Day 1 through Day 29
Secondary Clinical status at day 8, 15, 22, 29 Clinical status according to ordinal scale. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. Day 8, 15, 22, and 29
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure